Skip to main content
Immunome Inc. logo

Immunome Inc. — Investor Relations & Filings

Ticker · IMNM ISIN · US45257U1088 US Manufacturing
Filings indexed 395 across all filing types
Latest filing 2026-04-24 Annual Report
Country US United States of America
Listing US IMNM

About Immunome Inc.

https://immunome.com/

Immunome Inc. is a clinical-stage oncology company focused on developing targeted therapies to improve outcomes for cancer patients. The company specializes in creating first-in-class and best-in-class therapeutic candidates, with a primary focus on Antibody-Drug Conjugates (ADCs) and Radioligand Therapies (RLTs). Immunome utilizes a systematic, data-driven process to optimize each component of its drug candidates—antibody, linker, and payload—to address high unmet medical needs. Its clinical pipeline includes varegacestat, a gamma secretase inhibitor in a Phase 3 trial for desmoid tumors; IM-1021, a ROR1-targeted ADC in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand. The company also advances a portfolio of preclinical ADCs targeting various solid tumors.

Recent filings

Filing Released Lang Actions
ARS - Immunome Inc. (0001472012) (Filer)
Annual Report
2026-04-24 English
SCHEDULE 13G/A - Immunome Inc. (0001472012) (Subject)
Major Shareholding Notification
2026-03-26 English
4 - Immunome Inc. (0001472012) (Issuer)
Director's Dealing
2026-03-24 English
144 - Immunome Inc. (0001472012) (Subject)
Regulatory Filings
2026-03-20 English
10-K - IMMUNOME INC. (0001472012) (Filer)
Annual Report FY 2025
2026-03-03 English
8-K - IMMUNOME INC. (0001472012) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 3, 2026, reporting the company's financial results for the year ended December 31, 2025. It references a press release attached as Exhibit 99.1 containing the financial results and business update. The text explicitly states that the information is furnished and not filed, and the document itself is a current report rather than a full annual report or earnings release. The document length is 3772 characters, which is relatively short and mainly serves as an announcement of financial results with a press release attached. This fits the profile of an Earnings Release (ER) as it announces quarterly/periodical financial results with key highlights, rather than a full Annual Report (10-K) or Interim Report (IR).
2026-03-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.